Literature DB >> 22833233

Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis.

Maxime Samson1, Sylvain Audia, Jennifer Fraszczak, Malika Trad, Paul Ornetti, Daniela Lakomy, Marion Ciudad, Vanessa Leguy, Sabine Berthier, Julien Vinit, Patrick Manckoundia, Jean-Francis Maillefert, Jean-François Besancenot, Serge Aho-Glele, Nils Olivier Olsson, Bernard Lorcerie, Loïc Guillevin, Luc Mouthon, Philippe Saas, Andrew Bateman, Laurent Martin, Nona Janikashvili, Nicolas Larmonier, Bernard Bonnotte.   

Abstract

OBJECTIVE: Giant cell arteritis (GCA) is the most frequently occurring vasculitis in elderly individuals, and its pathogenesis is not fully understood. The objective of this study was to decipher the role of the major CD4+ T cell subsets in GCA and its rheumatologic form, polymyalgia rheumatica (PMR).
METHODS: A prospective study of the phenotype and the function of major CD4+ T cell subsets (Th1, Th17, and Treg cells) was performed in 34 untreated patients with GCA or PMR, in comparison with 31 healthy control subjects and with the 27 treated patients who remained after the 7 others withdrew.
RESULTS: Compared with control subjects, patients with GCA and patients with PMR had a decreased frequency of Treg cells and Th1 cells, whereas the percentage of Th17 cells was significantly increased. Furthermore, an analysis of temporal artery biopsy specimens obtained from patients affected by GCA for whom biopsy results were positive demonstrated massive infiltration by Th17 and Th1 lymphocytes without any Treg cells. After glucocorticoid treatment, the percentages of circulating Th1 and Th17 cells decreased, whereas no change in the Treg cell frequency was observed. The frequency of CD161+CD4+ T cells, which are considered to be Th17 cell precursors, was similar in patients and control subjects. However, these cells highly infiltrated GCA temporal artery biopsy specimens, and their ability to produce interleukin-17 in vitro was significantly enhanced in patients with GCA and patients with PMR and was correlated with a decrease in the phosphorylated form of STAT-1.
CONCLUSION: This study is the first to demonstrate that the frequency of Treg cells is decreased in patients with GCA and patients with PMR, and that CD161+CD4+ T lymphocytes, differentiated into Th1 cells and Th17 cells, are involved in the pathogenesis of GCA and PMR.
Copyright © 2012 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22833233     DOI: 10.1002/art.34647

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  50 in total

1.  Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: meta-analysis.

Authors:  M Yates; Y K Loke; R A Watts; A J MacGregor
Journal:  Clin Rheumatol       Date:  2013-09-12       Impact factor: 2.980

2.  Polymyalgia rheumatica and diverticular disease: just two distinct age-related disorders or more? Results from a case-control study.

Authors:  Rossana Scrivo; Maria Chiara Gerardi; Iolanda Rutigliano; Paola Sessa; Daniele Mipatrini; Gaetana Maria Grazia Stricchiola; Elena Pacella; Alessio Altobelli; Chiara Castellani; Cristiano Alessandri; Fulvia Ceccarelli; Manuela Di Franco; Roberta Priori; Valeria Riccieri; Antonio Sili Scavalli; Francesca Romana Spinelli; Giuseppe La Torre; Fabrizio Conti; Guido Valesini
Journal:  Clin Rheumatol       Date:  2018-05-07       Impact factor: 2.980

Review 3.  Relapse of polymyalgia rheumatica following adjuvanted influenza vaccine: A case-based review.

Authors:  Margaret F Bassendine; Simon H Bridge
Journal:  Eur J Rheumatol       Date:  2019-12-16

4.  An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy.

Authors:  Chie Miyabe; Yoshishige Miyabe; Klemen Strle; Nancy D Kim; John H Stone; Andrew D Luster; Sebastian Unizony
Journal:  Ann Rheum Dis       Date:  2016-12-07       Impact factor: 19.103

Review 5.  The immunoinhibitory PD-1/PD-L1 pathway in inflammatory blood vessel disease.

Authors:  Cornelia M Weyand; Gerald J Berry; Jörg J Goronzy
Journal:  J Leukoc Biol       Date:  2017-12-29       Impact factor: 4.962

6.  Polymyalgia rheumatica development in a patient under PI3K inhibitor therapy for chronic lymphocytic leukaemia.

Authors:  Sanah Sajawal; Sarah L Mackie; Peter Hillmen; Dennis McGonagle
Journal:  BMJ Case Rep       Date:  2017-11-08

7.  Neglected for too long? - CD8+ Tregs release NOX2-loaded vesicles to inhibit CD4+ T cells.

Authors:  Christoph T Berger; Christoph Hess
Journal:  J Clin Invest       Date:  2016-04-18       Impact factor: 14.808

Review 8.  Advances and challenges in the diagnosis and treatment of polymyalgia rheumatica.

Authors:  Tanaz A Kermani; Kenneth J Warrington
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-02       Impact factor: 5.346

Review 9.  Granuloma annulare development in a patient with rheumatoid arthritis treated with tocilizumab: case-based review.

Authors:  Eleftherios Pelechas; Alexandra Papoudou-Bai; Paraskevi V Voulgari; Alexandros A Drosos
Journal:  Rheumatol Int       Date:  2018-12-07       Impact factor: 2.631

Review 10.  Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica.

Authors:  Dario Camellino; Eric L Matteson; Frank Buttgereit; Christian Dejaco
Journal:  Nat Rev Rheumatol       Date:  2020-08-05       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.